bioRxiv Science⌕ Search

Biology subjects

Boisvert, M.

Publications and source records attributed to Boisvert, M..

4 recordsLinked to original sources

TRACR: an anterograde transneuronal tracing system for genetic access across synapses and longitudinal circuit analysis

Following neural signals as they converge onto and diverge from individual neurons is central to understanding circuit function and disease-related dysfunction. Existing anterograde transneuronal tracers are limited by cytotoxicity and incomplete genetic control over connected partners. To address these limitations, we adapted synthetic Notch designs to create TRanssynaptic Anterograde Circuit Readout (TRACR). Binding of the engineered ligand-receptor across synapses induces TRE-driven reporter transcription, enabling characterization of postsynaptic neurons. TRACR provides segregated genetic access to pre- and postsynaptic populations, and can be combined with markers, sensors, or effectors to expand circuit analysis. By applying TRACR at multiple synapses in the mouse visual system, we show that TRACR labels postsynaptic partners of sensory neurons, long-range projections and local inhibitory interneurons. TRACR signaling is reversible and fails to activate when synapses are absent or disrupted. Together, TRACR is an accessible, AAV-deliverable transneuronal reporting tool for longitudinal analysis of circuit assembly, degeneration, and repair. HIGHLIGHTSO_LITRACR adapts the synNotch system to signal across synapses for tracing postsynaptic targets. C_LIO_LITRACR identifies local and long-range postsynaptic targets in the mouse visual system. C_LIO_LITRACR activation requires intact synaptic connectivity rather than proximity. C_LIO_LITRACR signals are reversible, diminishing upon synapse loss and activating following assembly. C_LI

neuroscience↗

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have largely been ignored. We studied the role of BRAF fusion partners and found that they are necessary for transformation. In the setting of KIAA1549::BRAF, the most common fusion protein across brain tumors, we found that KIAA1549 is necessary for the oncogenicity of KIAA1549::BRAF and engenders a striking and specific dependency on the protein O-mannosyltransferase complex (POMT1/2). Specifically, we show that genetic silencing or pharmacologic inhibition of the protein O-mannosyltransferase complex (POMT1/2) reverses fusion-induced transformation, thereby representing a novel and MAPK independent therapeutic target. Furthermore, POMT1/2 is required to glycosylate and enable maturation of the K::B fusion protein. These findings represent a proof-of-concept for targeting the partners in oncogenic fusions as a potential cancer therapeutic strategy.

cancer biology↗

Deciphering Brain Organoids Heterogeneity by Identifying Key Quality Determinants

Brain organoids derived from human pluripotent stem cells (hPSCs) hold immense potential for modeling neurodevelopmental processes and disorders. However, their experimental variability and undefined organoid selection criteria for analysis hinder reproducibility. As part of the Bavarian ForInter consortium, we generated 72 brain organoids from distinct hPSC lines. We conducted a comprehensive analysis of their morphological and cellular characteristics at an early stage of their development. In our assessment, the Feret diameter emerged as a reliable, single parameter that characterizes brain organoid quality. Transcriptomic analysis further confirmed the reliability of this marker and identified a negative impact of mesenchymal cells on the abundance of organoid formation. High-quality organoids consistently displayed a lower mesenchymal cell presence. These findings offer a framework for enhancing brain organoid standardization and reproducibility, underscoring the need for morphological quality controls and the consideration of mesenchymal cell influence on organoid-based modeling. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=186 HEIGHT=200 SRC="FIGDIR/small/632763v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@11c214org.highwire.dtl.DTLVardef@1dcb643org.highwire.dtl.DTLVardef@1420141org.highwire.dtl.DTLVardef@6074e6_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

Improved genetically encoded fluorescent biosensors for monitoring of intra- and extracellular L-lactate

O_SCPLOWLC_SCPLOW-Lactate is increasingly appreciated as a key metabolite and signaling molecule in mammals. To enable investigations of both the inter- and intra-cellular dynamics of O_SCPLOWLC_SCPLOW-Lactate, we develop a second-generation green fluorescent extracellular O_SCPLOWLC_SCPLOW-Lactate biosensor, designated eLACCO2.1, and a red fluorescent intracellular O_SCPLOWLC_SCPLOW-Lactate biosensor, designated R-iLACCO1. Compared to the first-generation eLACCO1.1 ({Delta}F/F = 1.5 in cultured neurons), eLACCO2.1 exhibits better membrane localization and fluorescence response ({Delta}F/F = 8.1 in cultured neurons) with faster response kinetics to extracellular O_SCPLOWLC_SCPLOW-Lactate on the surface of live mammalian cells. R-iLACCO1 and its affinity variants exhibit large fluorescence responses to changes in O_SCPLOWLC_SCPLOW-Lactate concentration in vitro ({Delta}F/F = 15 to 22) and in live mammalian cells ({Delta}F/F = 5.5 to 11). We demonstrate that these biosensors enable cellular-resolution imaging of extracellular and intracellular O_SCPLOWLC_SCPLOW-Lactate in cultured mammalian cells.

molecular biology↗